Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MADRIGAL PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for MADRIGAL PHARMACEUTICALS, INC.

MDGL

MADRIGAL PHARMACEUTICALS, INC.

About MADRIGAL PHARMACEUTICALS, INC.

Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing therapies for metabolic liver diseases, primarily nonalcoholic steatohepatitis (MASH). Its flagship product, Rezdiffra (resmetirom), is a liver-directed oral therapy targeting fibrosis and inflammation. The company aims to address high unmet medical needs, expand indications, and obtain regulatory approvals globally, leveraging proprietary technology and strategic collaborations.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from MADRIGAL PHARMACEUTICALS, INC.

1
1
MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals Reports 127% Revenue Growth to $311.3 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals Reports 432% Revenue Growth Driven by Rezdiffra in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals Reports 362% Revenue Growth in Q3 2025, Launches Rezdiffra

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals Reports $212.8M Revenue in Q2 2025, Net Loss Improves

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals Reports $137.3 Million Revenue from Rezdiffra Launch, Net Loss Improves to $73.2 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals Reports $180.1M in Product Revenue and $465.9M Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
MADRIGAL PHARMACEUTICALS, INC. Madrigal Pharmaceuticals Reports Significant Financial Developments, Achieves $62.2M in Product Revenue for Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments